Literature DB >> 23345015

BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort.

Xiao-Bing Jiang1, Dong-Sheng He, Zhi-Gang Mao, Xiang Fan, Ni Lei, Bin Hu, Bing-Bing Song, Yong-Hong Zhu, Hai-Jun Wang.   

Abstract

Deranged metabolic profiles and insulin resistance (IR) have been documented in patients with prolactinomas. Few data are yet available on the apolipoprotein (apo) B/apoA-I ratio and its relationship with IR in patients with prolactinomas. This study was aimed to evaluate the level of apoB/apoA-I ratio and its association with IR in a Chinese subgroup with prolactinomas. Twenty-three prolactinoma patients and 20 healthy controls were enrolled in this study. The clinical anthropometric parameters and laboratory evaluation were collected. Insulin sensitivity was estimated using homeostatic model assessment [homeostasis model assessment of insulin resistance (HOMA-IR)]. Waist circumference and body weight index (BMI) were significantly higher in patients with prolactinomas than those in the controls (p < 0.05). Meanwhile, the prevalence of general and abdominal obesity seemed more pronounced in male patients compared to that in healthy subjects (57.14 vs. 0 % and 71.43 vs. 16.7 %, respectively). Furthermore, fasting glucose, insulin, HOMA-IR, triglyceride, and apoB/apoA-I ratio were also significantly higher in prolactinoma patients, but with lower level of apoA-I (p < 0.05). Univariate regression analysis revealed that prolactin, waist circumference, BMI, and presence of hypogonadism were significantly associated with IR (p < 0.05). However, only BMI [odds ratio (OR) = 1.937, 95 % confidence interval (CI) 1.112-3.375, p = 0.02] and prolactin (OR = 5.173, 95 % CI 1.073-24.94, p = 0.041) were shown to be independent predictors for the presence of IR in multivariate logistic analysis. This study confirmed the altered metabolic profile, including body weight gain, IR, disordered lipids, and apolipoproteins in prolactinoma patients. Prolactin and BMI were independently associated with IR. The effect of apoB/apoA-I ratio on IR is warranted to be determined in further studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345015     DOI: 10.1007/s13277-013-0660-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

Review 2.  Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993-2009.

Authors:  B Xi; Y Liang; T He; K H Reilly; Y Hu; Q Wang; Y Yan; J Mi
Journal:  Obes Rev       Date:  2011-10-31       Impact factor: 9.213

3.  Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.

Authors:  Katarina Berinder; Thomas Nyström; Charlotte Höybye; Kerstin Hall; Anna-Lena Hulting
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

4.  Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats.

Authors:  Sunmin Park; Da Sol Kim; James W Daily; Sung-Hoon Kim
Journal:  Diabetes Metab Res Rev       Date:  2011-09       Impact factor: 4.876

5.  Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma.

Authors:  Christoph Schmid; Diane L Goede; Renward S Hauser; Michael Brändle
Journal:  Swiss Med Wkly       Date:  2006-04-15       Impact factor: 2.193

6.  BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.

Authors:  Cintia M dos Santos Silva; Flavia R P Barbosa; Giovanna A B Lima; Leila Warszawski; Rosita Fontes; Romeu C Domingues; Mõnica R Gadelha
Journal:  Obesity (Silver Spring)       Date:  2010-06-17       Impact factor: 5.002

7.  Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes.

Authors:  E M Dahlén; T Länne; J Engvall; T Lindström; E Grodzinsky; F H Nystrom; C J Ostgren
Journal:  Diabet Med       Date:  2009-04       Impact factor: 4.359

Review 8.  Focus on prolactin as a metabolic hormone.

Authors:  Nira Ben-Jonathan; Eric R Hugo; Terry D Brandebourg; Christopher R LaPensee
Journal:  Trends Endocrinol Metab       Date:  2006-03-06       Impact factor: 12.015

9.  Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zhiyuan Zhang; Thomas A Pearson; Lars Berglund
Journal:  Am J Cardiol       Date:  2010-11-01       Impact factor: 2.778

10.  Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.

Authors:  Mirjana Doknic; Sandra Pekic; Milos Zarkovic; Milica Medic-Stojanoska; Carlos Dieguez; Felipe Casanueva; Vera Popovic
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

View more
  3 in total

1.  Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.

Authors:  Xiao-Bing Jiang; Cui-Ling Li; Dong-Sheng He; Zhi-Gang Mao; Dong-Hong Liu; Xiang Fan; Bin Hu; Yong-Hong Zhu; Hai-Jun Wang
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

2.  Preterm born 9-year-olds have elevated IGF-1 and low prolactin, but levels vary with behavioural and eating disorders.

Authors:  A Kistner; E Deschmann; L Legnevall; M Vanpee
Journal:  Acta Paediatr       Date:  2014-08-04       Impact factor: 2.299

3.  The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.

Authors:  Robert Krysiak; Joanna Okrzesik; Boguslaw Okopien
Journal:  Endocrine       Date:  2014-09-20       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.